Collins Stewart Initiates Coverage on Macrovision (MVSN) with a Buy
MVSN Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 8 | New: 25
Collins Stewart initiates coverage on Macrovision (Nasdaq: MVSN) with a Buy. Price target $32.
Collins analyst says, "The stock trades 13x our CY10 EPS estimate, more than a 50% discount to its peer group average. The company made a slew of acquisitions and divestitures, and we believe that as investors gain familiarity with the transformed company, multiple expansions will occur, especially in light of the company's greater relative stability, lower downside risk, and greater potential for market share gains. Possessing patents in key niches, it has a highly defendable technology advantage over its peers, particularly in the current recessionary environment."
To see more analyst ratings on MVSN Click Here.
Macrovision Solutions Corporation provides a set of solutions that enable businesses to protect, enable and distribute their digital goods to consumers and allows consumers the ability to discover and manage digital media across multiple channels.
Collins analyst says, "The stock trades 13x our CY10 EPS estimate, more than a 50% discount to its peer group average. The company made a slew of acquisitions and divestitures, and we believe that as investors gain familiarity with the transformed company, multiple expansions will occur, especially in light of the company's greater relative stability, lower downside risk, and greater potential for market share gains. Possessing patents in key niches, it has a highly defendable technology advantage over its peers, particularly in the current recessionary environment."
To see more analyst ratings on MVSN Click Here.
Macrovision Solutions Corporation provides a set of solutions that enable businesses to protect, enable and distribute their digital goods to consumers and allows consumers the ability to discover and manage digital media across multiple channels.
You May Also Be Interested In
- UPDATE: Oppenheimer Starts Jazz Pharmaceuticals (JAZZ) at Outperform
- Imperial Capital Starts Primoris Services Corporation (PRIM) at Outperform
- Needham & Company Maintains a 'Buy' on PetSmart (PETM); Raising PT and Estimates as EPS And SSS Beat Expectations
Create E-mail Alert Related Categories
New CoverageRelated Entities
Collins StewartSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
